Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection

The mucosal immune system is the largest component of the entire immune system, having evolved to provide protection at the main sites of infectious threat: the mucosae. As SARS-CoV-2 initially infects the upper respiratory tract, its first interactions with the immune system must occur predominantly at the respiratory mucosal surfaces, during both inductive and effector phases of the response. However, almost all studies of the immune response in COVID-19 have focused exclusively on serum antibodies and systemic cell-mediated immunity including innate responses. This article proposes that there is a significant role for mucosal immunity and for secretory as well as circulating IgA antibodies in COVID-19, and that it is important to elucidate this in order to comprehend especially the asymptomatic and mild states of the infection, which appear to account for the majority of cases. Moreover, it is possible that mucosal immunity can be exploited for beneficial diagnostic, therapeutic, or prophylactic purposes.

[1]  Marco Piñón,et al.  I Overview , 2020, The Diaries and Letters of Lord Woolton 1940-1945.

[2]  A. Gingras,et al.  Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients , 2020, Science Immunology.

[3]  P. Enríquez,et al.  SARS-CoV-2-RNA viremia is associated to hypercytokinemia and critical illness in COVID-19 , 2020, medRxiv.

[4]  C. Schiffer,et al.  A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction , 2020, Nature Communications.

[5]  S. Zolla-Pazner,et al.  Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, medRxiv.

[6]  J. Dye,et al.  Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.

[7]  O. Schwartz,et al.  IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.

[8]  A. Fischer.  Resistance of children to Covid-19. How? , 2020, Mucosal Immunology.

[9]  A. Aguzzi,et al.  Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19 , 2020, bioRxiv.

[10]  W. Wang,et al.  Viral and host factors related to the clinical outcome of COVID-19 , 2020, Nature.

[11]  M. Merad,et al.  Immunology of COVID-19: Current State of the Science , 2020, Immunity.

[12]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[13]  G. Schett,et al.  IgA subclasses have different effector functions associated with distinct glycosylation profiles , 2020, Nature Communications.

[14]  P. Montgomery,et al.  Ocular Mucosal Immunity , 2015, Mucosal Immunology.

[15]  J. Nurkić,et al.  Diagnostic Significance of Reduced IgA in Children , 2014, Medical archives.

[16]  L. James,et al.  Translocalized IgA mediates neutralization and stimulates innate immunity inside infected cells , 2014, Proceedings of the National Academy of Sciences.

[17]  Jerome H. Kim,et al.  Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG , 2013, Proceedings of the National Academy of Sciences.

[18]  P. Brandtzaeg.  Secretory immunity with special reference to the oral cavity , 2013, Journal of oral microbiology.

[19]  C. Czerkinsky,et al.  Sublingual vaccination , 2011, Human vaccines.

[20]  J. Mcghee,et al.  Mucosal Vaccines: An Overview , 2005, Mucosal Immunology.

[21]  M. Mulligan,et al.  Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. , 2004, AIDS research and human retroviruses.

[22]  서정헌,et al.  반도체 공정 overview , 2001 .

[23]  R. Pabst,et al.  Bronchus-Associated Lymphoid Tissue (BALT) Is Not Present in the Normal Adult Lung but in Different Diseases , 2000, Pathobiology.

[24]  E. Butcher,et al.  Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. , 1997, The Journal of clinical investigation.

[25]  M. Kilian,et al.  Anti‐inflammatory activity of human IgA antibodies and their Fabα fragments: inhibition of IgG‐mediated complement activation , 1989, European journal of immunology.

[26]  D. Delacroix,et al.  Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense? , 1987, Annals of internal medicine.

[27]  M. Cooper,et al.  Analysis of paraprotein transport into the saliva by using anti-idiotype antibodies. , 1987, Journal of immunology.

[28]  K. Callow.  Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection , 1985, Journal of Hygiene.

[29]  J. Griffiss,et al.  IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. , 1983, Journal of immunology.

[30]  Sara Invitto,et al.  Current state of the science , 2015 .

[31]  R. Blumberg,et al.  Immunoglobulin Transport and Immunoglobulin Receptors , 2015 .

[32]  P. Brandtzaeg.  Immunobiology of the Tonsils and Adenoids , 2015 .

[33]  N. Mantis,et al.  Biological Activities of IgA , 2015 .

[34]  A. Luster,et al.  Chapter 40 - Lymphocyte Trafficking to Mucosal Tissues , 2015 .

[35]  B. Lambrecht,et al.  Overview: The Mucosal Immune System , 2015 .

[36]  J. Woof.  Chapter 17 – Mucosal Immunoglobulins , 2015 .

[37]  C. Kaetzel.  Mucosal immune defense : immunoglobulin A , 2007 .

[38]  L. Hammarström,et al.  IgA-Associated Diseases , 2007 .

[39]  M. Russell.  Biological Functions of IgA , 2007, Mucosal Immune Defense: Immunoglobulin A.

[40]  J. Mestecky,et al.  Appendix I – Collection and Processing of Human Mucosal Secretions , 2005 .

[41]  B. Murphy,et al.  Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. , 1995, Vaccine.